SCHEMBL12802461

SCHEMBL12802461

FC(F)N1Cc2ccccc2C1c1nc(NCC(c2ccccc2)N2CCCC2)nc(N2CCOCC2)n1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSL P07711 3/20 0.42
CTSB P07858 3/20 0.42
CTSS P25774 3/20 0.42
CTSK P43235 3/20 0.42
HTT P42858 2/20 0.40
LMNA P02545 4/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
PIK3CD O00329 5/20 0.35
PIK3CA P42336 5/20 0.35
PIK3CB P42338 5/20 0.35
PIK3CG P48736 5/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
POLB P06746 1/20 0.34
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2442701 0.77 L3MBTL1 (0.38) HTTLMNAALDH1A1GAAPIK3CD
SCHEMBL12802380 0.73 PIK3CB (0.67) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL12802451 0.69 PIK3CA (0.37) LMNASMN1; SMN2PIK3CDPIK3CAPIK3CB
SCHEMBL2520544 0.67 PIK3CB (0.39) HTTPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL27937123 0.66 PIK3CB (0.45) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL28403487 0.62 PIK3CA (0.48) HTTLMNAALDH1A1GAASMN1; SMN2
SCHEMBL5172735 0.59 CYP1A2 (0.56) LMNAALDH1A1GAATSHRSLC6A3
SCHEMBL14438348 0.58 ALDH1A1 (0.47) LMNAALDH1A1SMN1; SMN2TSHRSLC6A3
SCHEMBL8276876 0.57 ALDH1A1 (0.49) LMNAALDH1A1SMN1; SMN2TP53SLC6A3
SCHEMBL1462411 0.57 CCR3 (0.50) LMNAALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150265625-A1 (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES PATHWAY THERAPEUTICS, INC. 2015-09-24 US disclosed
US-9056852-B2 (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases MEI PHARMA, INC. (US) 2015-06-16 US disclosed
US-20120252802-A1 (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES PATHWAY THERAPEUTICS INC. (US) 2012-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252802-A1 (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES CCNI, CCNK, CCNA1 CTSL 865/4885CTSB 2296/4885CTSS 2370/4885
US-20150265625-A1 (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES CCNI, CCNK, CCNA1 CTSL 865/4885CTSB 2296/4885CTSS 2370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.